Rxwire
In the news · 48h FDA 32 Eli Lilly 16 Roche 10 Johnson & Johnson 8 AstraZeneca 4 AbbVie 3 Merck & Co. (MSD) 3 Pfizer 2
Approvals & regulatory · first seen 1h ago, updated 1h ago

FDA approves Mirum’s drug for ultra-rare soft tissue disease

1 outlet FDA

The FDA has approved the third treatment for a debilitating genetic disease that turns muscle and connective tissue to bone. Mirum Pharmaceuticals’ zilurgisertib, which blocks the ALK2 receptor, will be marketed as Atebrioz for patients ...

Summary from Endpoints News.

Coverage 1 article · 1 outlet

  1. Endpoints News
    FDA approves Mirum’s drug for ultra-rare soft tissue disease